The human cationic amino acid transporter hCAT-1 is almost ubiquitously expressed and probably the most important entity for supplying cells with extracellular arginine, lysine, and ornithine. We have previously shown that hCAT-1-mediated transport is decreased after protein kinase C (PKC) activation by phorbol 12-myristate 13-acetate (PMA) (Grä f, P., Fö rstermann, U., and Closs, E. I. 
The cationic amino acid transporter CAT-1 represents most likely the major carrier for cationic amino acids in most mammalian cells (for review see Refs. 1 and 2). With the exception of the adult liver, CAT-1 expression has been found in every tissue and cell line so far investigated (3) . Homozygous deletion of the CAT-1 gene in mice results in anemia and perinatal death, underlining the importance of this carrier (4) . The transport characteristics of CAT-1 are consistent with the so called system y ϩ , a Na ϩ -and pH-independent transport system selective for cationic amino acids (5) (6) (7) . Two related transporters, CAT-2B and CAT-3, exhibit similar transport properties, yet differ in their expression pattern. CAT-2B is a cytokine-inducible transporter that is always co-expressed with CAT-1. However, CAT-1 can apparently not always replace the function of CAT-2B in supplying the substrate arginine to the inducible nitric-oxide synthase (8, 9) . This suggests that each CAT isoform operates in a distinct compartment of the plasma membrane. Besides its general role in delivery of essential and semi-essential amino acids for protein synthesis, a specific role of CAT-1 has been proposed for providing substrate for (endothelial NO synthase-mediated) NO synthesis in endothelial cells (for review, see Ref. 1) , for polyamine synthesis in regenerating hepatocytes (10) , and for polyamine and collagen synthesis in vascular smooth muscle cells (11) . Despite its almost ubiquitous expression, CAT-1 underlies a complex regulation. For the rat orthologue, extensive transcriptional as well as translational regulation has been demonstrated (Ref. 12 and references therein). In addition, several groups have reported that CAT-1 activity can be regulated at the post-translational level (for review see Ref. 1) . We have previously shown that hCAT-1-mediated 1 transport is down-regulated in both Xenopus laevis oocytes and human endothelial cells, upon activation of protein kinase C (PKC). This reduction in transport activity was not accompanied by a decrease in the total level of hCAT-1 protein (13) . A more recent study confirmed these findings in porcine pulmonary artery endothelial cells and identified classical PKC isoforms, most likely PKC␣, as responsible for this down-regulation (14) . CAT-1 exhibits three consensus sequences for PKC phosphorylation that are located in the fifth and sixth putative intracellular loops according to the model by Albritton et al. (15) that suggests 14 membrane-spanning domains. These sites are conserved between human, rat, and mouse CAT-1. In the present study, we examined more closely the mechanism of the PKC-mediated down-regulation of CAT-1.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis-Deletion of the PKC binding sites of hCAT-1 was achieved by site-directed mutagenesis of the hCAT-1 cDNA inserted in the pSP64T vector (pSPhCAT-1AB1) (6) using a QuikChange mutagenesis kit (Stratagene) and the oligonucleotides listed in Table I . The entire coding region of the resulting plasmid (pSPhCAT-1S476A/S482A/S557A) was sequenced to ensure that no additional mutation had been introduced into the hCAT-1 cDNA.
EGFP Fusion Constructs-The constructs hCAT-1⅐EGFP-pSP64T (for transcription of cRNA for X. laevis oocytes) and hCAT-1/pEGFP-N1 * This work was supported by Grants Cl 100/4-1 and Collaborative Research Center SFB 553 Project B4 from the Deutsche Forschungsgemeinschaft. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
(for expression in mammalian cells) encode EGFP fused to the C terminus of hCAT-1 and have been described earlier (16) . The hCAT-1S476A/S482A/S557A /pEGFP-N1 construct was generated by introducing a 840-bp PCR fragment from pSPhCAT-1S476A/S482A/S557A into the KpnI/XmaI sites of the hCAT-1⅐pEGFP-N1 (oligonucleotides used for PCR: CTTCTAGGATCCATGTTTCC and GATCCCGGGCCT-TGCACTGGTCCAAGT, sense and antisense, respectively).
Transport Studies in X. laevis Oocytes-hCAT-1⅐EGFP-pSP64T and pSPhCAT-1S476A/S482A/S557A were linearized with EcoRI, and cRNA was prepared by in vitro transcription from the SP6 promoter (mMessage mMachine in vitro transcription kit; Ambion, AMS Biotechnology Europe, Cambridgeshire, UK). 30 ng of cRNA (in 40 nl of H 2 O) were injected into each X. laevis oocyte (Dumont stages V-VI). Oocytes injected with 40 nl of water were used as controls.
Arginine uptake was determined 3 days after injection of cRNA as previously described (7) . Briefly, the oocytes were equilibrated for 2 h at 18°C in uptake solution (100 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 5 mM HEPES, 5 mM Tris, pH 7.5) containing 100 M of unlabeled arginine. The oocytes were then transferred to the same solution containing 100 nM PMA in 0.1% Me 2 SO or 0.1% Me 2 SO alone (30 min, 20°C). After the preincubation, the oocytes were washed in uptake solution containing 100 M arginine and transferred to the same solution supplemented with 5 Ci/ml L-[ 3 H]arginine (ICN, Eschwege, Germany; L- [4,5- 3 H]arginine, 39 Ci/mmol). After incubation for 15 min at 20°C, the oocytes were washed four times in ice-cold uptake solution and solubilized individually in 2% SDS. The incorporated radioactivity was determined in a liquid scintillation counter.
Cryostat Sections of X. laevis Oocytes-Three days after injection with hCAT-1⅐EGFPcRNA, the oocytes were treated with 100 nM PMA or 0.1% Me 2 SO alone (30 min, 20°C) in uptake solution containing 100 M arginine. The oocytes were then washed five times in phosphate-buffered saline (PBS) and immediately frozen in liquid nitrogen in tissue freezing medium (Leica Instruments, Jung). 12-m cryostat sections were made at Ϫ15°C, and fluorescent micrographs were taken using a Leitz DMRB fluorescence microscope (Leica, Bensheim, Germany) and a Nikon DXM1200 digital camera (Nikon Co., Tokyo, Japan).
Cell Culture-The human U373 MG glioblastoma and the DLD-1 colon carcinoma cell lines were obtained from ATCC (Manassas, VA). The cells were grown in Iscove's medium or Dulbecco's modified Eagle's medium, respectively, supplemented with 10% heat-inactivated fetal bovine serum. U373 MG-derived clones described below were maintained in medium containing 600 g/ml G418. The cells were regularly tested for mycoplasma infection using 4,6-diamindine 2-phenylindole dihydrochloride (Roche Applied Science). No contamination was detected.
Transfection of U373MG Glioblastoma Cells-The cells were seeded into 6-well plates (2 ϫ 10 5 cells/well) 1 day before transfection using the Effectene transfection kit (Qiagen). Plasmid DNA (0.5 g) and 3.2 l of Enhancer were added to 100 l of transfection buffer, mixed with 10 l of Effectene, and incubated at room temperature for 5 min. Then 600 l of medium containing 10% serum were added. The cells were washed with PBS and incubated with the transfection reagent for 6 h at 37°C. Two days after transfection, the cells were split into 10-cm dishes. Stably transfected cell clones were selected in medium containing 600 g/ml G418. For each construct, several independent clones were singled out.
Confocal Microscopy-The cells were grown on cover glass-bottomed chamber slides (Nalge Nunc, Naperville, IL) and either directly analyzed or fixed for 5 min with 4% paraformaldehyde in PBS and washed with PBS. The cells were analyzed with a Zeiss 510 confocal laser scan microscope equipped with a UV laser (Zeiss, Oberkochem, Germany). The images were collected with a 1.4 numerical aperture 63ϫ Zeiss Plan-aprochromat objective using identical scanning parameters.
Transport Studies in Human Cells-Cells grown to confluence in 96-well plates were preincubated for the indicated time at 37°C in 100 l well Ϫ1 of medium containing PMA or other compounds in the concentration given in the figure legend. The cells were then washed twice with Locke's solution (154 mM NaCl, 5.6 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 3.6 mM NaHCO 3 , 5.6 mM glucose, pH 7.4) containing 100 M of arginine, before incubation in the same solution containing in addition 5-10 Ci/ml L-[ 3 H]arginine (39 Ci/mmol) for 30 s at 37°C. The endogenous hCAT-1 transport in DLD-1 colon carcinoma cells was measured in the presence of additional 2 mM leucine. The cells were then immediately transferred on ice, washed three times with ice-cold Locke's solution, and lysed in 0.5 M NaOH (50 l/well, 30 min at 4°C). After neutralization of the lysates with 50 l of 0.5 M HCl and 100 l of buffer A (50 mM Tris/HCl pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA), the protein content of each sample was determined using the Bradford reaction (Bio-Rad). The radioactivity in the samples was measured by liquid scintillation counting. For transfected cells, the transport values of cells stably transfected with pEGFP-N1 were subtracted. The background radioactivity derived from arginine bound to the cells (determined by addition of Locke's solution containing 100 M L-[ 3 H]arginine (5-10 Ci/ml) followed by immediate washing steps) were subtracted from all values (usually less than 10% of experimental values).
Biotinylation of Cell Surface Proteins-Biotinylation of cell surface proteins was performed as described (17) with slight modifications. Briefly, the cells were grown to confluence in 10-cm dishes, rinsed with ice-cold PBS containing 0.1 mM CaCl 2 and 0.1 mM MgCl 2 (PBS-Ca/Mg), and incubated in the same solution supplemented with 1 mg/ml sulfosuccinimidobiotin (EZ-Link™ sulfosuccinimidyl-2-(biotinoamido)ethyl-1,3-dithiopropionate; Pierce) for 20 min at 4°C. The cells were then rinsed three times with PBS-Ca/Mg containing 100 mM glycine and incubated in this buffer for 30 min at 4°C to quench any unbound biotin. The cells were then lysed by the addition of 1 ml of radioimmunoprecipitation assay buffer (100 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing protease inhibitors (complete; Roche Applied Science) for 1 h at 4°C. After removal of the cellular debris protein concentration of the lysates was determined using the Bradford reaction. Where indicated, lysates were treated with N-glycosidase F (Roche Applied Science; 2 units/100 g protein, 30 min at 37°C). Biotinylated proteins (about 150 g of U373 lysates or 800 g of DLD-1 lysates) were batch-extracted using avidin-coated Sepharose beads (immobilized NeutrAvidin™ (Pierce), 4°C, overnight) and then released from the beads by incubation in 30 l of sample buffer (50 mM Tris/HCl, pH 6.8, 2 mM EDTA, 4% SDS, 8 M urea, 3.5% 2-mercaptoethanol, 0.001% bromphenol blue, 30 min at room temperature). To total cell lysates, an equal volume sample buffer was added.
Western Blots-Lysates and cell surface proteins were separated in 10% SDS-PAGE and then blotted to nitrocellulose membranes (Protran83; Schleicher & Schuell). Staining for EGFP fusion proteins and hCAT-1, respectively, was achieved by sequential incubations in: Blotto (50 mM Tris/HCl, pH 8, 2 mM CaCl 2 , 0.01% antifoam A (Sigma), 0.05% Tween 20, 5% nonfat dry milk) containing 10% goat serum (2 h at room temperature), a dilution of the first antibody (1:500 of an anti-GFP peptide antibody (Clontech), or a 1:200 dilution of our hCAT-1 antibody (13) in PBS containing 1% bovine serum albumin and 0.1% Tween 20 (overnight, 4°C), three times Blotto (15 min, room temperature), a 1:10000 dilution in Blotto of a peroxidase-conjugated secondary goat anti-rabbit IgG antibody (Calbiochem, Bad Soden, Germany) (1 h, room temperature); three times TBST (10 mM Tris/HCl, pH 8, 150 mM NaCl, 0.05% Tween 20), once in TBS (10 mM Tris/HCl pH 8; 150 mM NaCl) and finally for 1 min with chemiluminescence reagent (Renaissance; PerkinElmer Life Sciences). X-ray film (Agfa, Leverkusen, Germany) was then immediately exposed to the membranes. The membranes were stripped (in 62.5 mM Tris/HCl, pH 6.8, 2% SDS, 100 mM ␤-mercaptoethanol for 30 min at 50°C) and stained with a monoclonal antibody to ␤-tubulin (1:1000; Sigma) and a peroxidase-conjugated secondary goat anti-mouse IgG antibody (1:3000; Sigma).
In Vivo Phosphorylation and Immunoprecipitation-Cells grown to confluence in 3-cm dishes were first incubated for 90 min at 37°C in phosphate-free Dulbecco's modified Eagle's medium (Sigma), 5% fetal bovine serum and then for 2.5 h in medium containing 750 Ci/ml [ 32 P]orthophosphate (Amersham Biosciences). During the last 30 min, the cells were treated with 100 nM PMA or 0.1% Me 2 SO. The cells were then washed three times with ice-cold PBS and lysed for 1 h at 4°C in 0.5 ml/well radioimmunoprecipitation assay buffer containing protease inhibitors (complete; Roche Applied Science) and phosphatase inhibitors (25 mM NaF; 10 mM ␤-glycerophosphate; 1 mM sodium vanadate, 10 nM okadaic acid). After removal of the cellular debris, the lysates were treated with N-glycosidase F (see above) and precleared with protein A-agarose (Affi-Gel Protein A; Bio-Rad). hCAT-1⅐EGFP protein was then immunoprecipitated using a polyclonal GFP anti-serum (Synaptic Systems, Göttingen, Germany; 1:200) and protein A-agarose (incubation overnight, 4°C). After washing five times with PBS, immobilized protein was released with 30 l of sample buffer (see above) for 10 min at 60°C. 25 l of each sample was resolved by 8% SDS-PAGE. The gels were dried, and phosphorylated protein was visualized using a Personal-FX molecular imager (Bio-Rad). In parallel experiments hCAT-1⅐EGFP was immunoprecipitated from 300 l of lysate obtained in the same way from unlabeled cells and detected by Western blot analysis using an anti-GFP monoclonal antibody (Clontech; 1:2000).
RESULTS

PMA-induced Internalization of hCAT-1 Expressed in X. laevis
Oocytes-To visualize the cell surface expression of hCAT-1, the enhanced green fluorescent protein fused to the C terminus of hCAT-1 was expressed in X. laevis oocytes. In our earlier report, we have shown that this fusion protein has transport properties indistinguishable from wild type hCAT-1 (16) . Fluorescent micrographs revealed a discernible decrease of hCAT-1⅐EGFP expression in the plasma membrane of the oocytes upon PMA treatment (100 nM, 30 min; Fig. 1, A and B) . The same PMA treatment lead to a 55 Ϯ 7% reduction in hCAT-1⅐EGFP-mediated arginine transport, consistent with our previous studies using wild type hCAT-1 (13) (Fig. 1C) .
PKC-mediated Internalization of hCAT-1 Expressed in Human Cells-hCAT-1⅐EGFP stably expressed in several independent U373MG glioblastoma cell clones was localized in the plasma membrane as well as in intracellular vesicles as evidenced by confocal microscopy. In the plasma membrane, a distinct fluorescence pattern could be detected with the strongest fluorescence intensity always observed in the ruffled borders (Fig. 2) . A 15-30-min treatment of the cells with 100 nM PMA led to a marked down-regulation of hCAT-1⅐EGFP expressed in the plasma membrane. In contrast, the subcellular distribution did not change upon treatment of cells with Me 2 SO alone. To quantify the cell surface expression of hCAT-1, cell surface proteins were biotinylated and separated from internal proteins using avidin-coated beads. Western blot analysis demonstrated a reduction of hCAT-1⅐EGFP in the cell surface protein fraction (75 Ϯ 5% of control) but not in total cell lysates (100 Ϯ 3% of control) (Fig. 3) . The PMA effect on the cell surface expression was abolished in the presence of the PKC inhibitor BIM I (99 Ϯ 4% of control). No signal for the cytosolic ␤-tubulin was detected in the cell surface protein fraction, confirming the efficiency of the separation method.
Transport studies measuring the initial uptake of 100 M L-[
3 H]arginine confirmed that the reduced cell surface expression of hCAT-1⅐EGFP in PMA-treated cells was accompanied by a reduction in the hCAT-1⅐EGFP-mediated transport rate (down to 57 Ϯ 4%) (Fig. 4) . Pretreatment with BIM I reduced the PMA effect significantly. PDBu, another PKC-activating phorbol ester, reduced the transport rate to a similar extent as PMA (down to 63 Ϯ 4%). In contrast, BIM I in the absence of an active phorbol ester and the inactive phorbol ester 4␣-PDD had no effect (103 Ϯ 3% and 99 Ϯ 5%, respectively).
So far, our studies were performed on hCAT-1 overexpressed exogenously in X. laevis oocytes or human cells. We therefore aimed to confirm that the activation of PKC also causes an internalization of endogenously expressed hCAT-1. In a screen of various human cell lines, DLD-1 colon carcinoma cells exhibited the highest system y ϩ -mediated transport rates and hCAT-1 expression (data not shown) and were therefore chosen for our analyses. Western blots with an antibody against the C terminus of hCAT-1 revealed no significant changes in hCAT-1 protein expression in total lysates of cells treated either with Me 2 SO alone, PMA alone, or PMA plus BIM I (Fig. 5) . In contrast, the cell surface expression of hCAT-1 was markedly reduced in PMA-treated cells (55 Ϯ 8% of control). No significant reduction was seen when cells were exposed to PMA together with BIM I (89 Ϯ 11%).
Reversibility of the PMA-mediated Reduction in Arginine Transport-Measurements of arginine transport in DLD-1 colon carcinoma cells were performed in the presence of 2 mM cold leucine to block arginine transport mediated by transport systems other than hCAT-1 (Figs. 6 and 7) . Only the PKC-activating phorbol esters PMA und PDBu lead to a significant reduction in arginine transport (73 Ϯ 5 and 72 Ϯ 4% of control, respectively). The simultaneous presence of BIM I abolished the effect of both PMA and PDBu (107 Ϯ 5 and 100 Ϯ 6% of control, respectively). Neither BIM I alone nor 4␣-PDD had an effect on the arginine transport rate. In cells pretreated with cyclohexamide (10 g/ml) for 3 h, the PMA-induced reduction of arginine transport was not larger than in cells with intact protein synthesis, indicating that PMA does not accelerate the breakdown of hCAT-1 (Fig. 7A ). An unaltered hCAT-1 expression was confirmed by Western blot analysis. In addition, washout experiments demonstrated that the PMA effect was reversible within 1 h (Fig. 7B) . The hCAT-1 protein did not increase over time during the washout period, indicating that the recovery of transport activity was not due to accelerated synthesis of hCAT-1.
Indirect Action of PKC on hCAT-1-To elucidate whether PKC directly phosphorylates hCAT-1, we removed all potential PKC phosphorylation sites by mutation of the respective serine residues (amino acids 476, 482, and 557) to alanine. Stable expression of the mutant hCAT-1 fused to EGFP (hCAT-1S476A/S482A/S557A/pEGFP-N1) in U373MG cells revealed a similar subcellular distribution as observed for the wild type hCAT-1 in all independent cell clones (supplemental figure,  panels B and C) . Also, the transport activity was comparable for both mutant and wild type hCAT-1 (supplemental figure,  panel D) . A 15-30-min treatment with 100 nM PMA lead to a similar down-regulation in cell surface expression of the mutated transporter as observed for the wild type hCAT-1 (Fig. 8) . Again, the subcellular distribution of the mutant did not change after treatment with Me 2 SO alone. In addition, PMA treatment lead to an undiminished reduction in arginine transport mediated by the mutant hCAT-1 expressed in U373MG cells. This reduction was dependent on the activation of PKC (Fig. 9A) . Similarly, the arginine transport in X. laevis oocytes mediated by the mutant hCAT-1 was inhibited to a similar extent as observed for the wild type transporter (Fig. 9B) .
To examine more directly whether hCAT-1 is phosphorylated in response to PKC activation, we performed in vivo phosphorylation studies in U373 cells overexpressing hCAT-1⅐EGFP. Using a GFP antibody, radiolabeled protein was precipitated from these cells but not from cells overexpressing EGFP alone (Fig. 10) . The protein precipitated from N-glycosidase F-treated lysates migrated the same distance in SDS-PAGE as deglycosylated hCAT-1⅐EGFP. The same was true for the glycosylated protein (data not shown). However, the intensity of the phospho signal was not increased upon PMA treatment. Western blots performed in parallel showed that the same amount of hCAT-1⅐EGFP was precipitated from Me 2 SO-and PMA-treated cells. Together, these results suggest that hCAT-1 is in fact a phosphorylated protein, but the phosphorylation does not change with PKC activation.
DISCUSSION
Three major conclusions can be drawn from our study. First, activation of PKC leads to a decrease in cell surface expression of hCAT-1. The reduced cell surface expression was observed for fusion proteins between hCAT-1 and EGFP overexpressed in X. laevis oocytes and in U373MG human glioblastoma cells as well as for hCAT-1 expressed endogenously in DLD-1 colon carcinoma cells. In all cases, internalization of hCAT-1 was accompanied by a similar reduction of hCAT-1-mediated transport. These data indicate that the PKC-induced transport inhibition is the result of transporter internalization rather than modifications in hCAT-1 catalytic activity. The PKC inhibitor BIM I markedly reduced both hCAT-1 internalization and transport inhibition mediated by the PKC-activating phorbol ester PMA. In addition, transport inhibition was also observed with another PKC-activating phorbol ester, PDBu, but not with the inactive phorbol ester 4␣-PDD. Internalization of the endogenously expressed hCAT-1 and inhibition of hCAT-1-mediated arginine transport occurred to a similar extent as observed for the overexpressed transporter fusion protein, indicating that the fusion partner EGFP had no influence on the subcellular distribution of hCAT-1.
Second, the PMA effect seems to be reversible as evidenced by transport studies in DLD-1 cells. In the presence of 2 mM leucine during the arginine uptake measurements, DLD-1 cells exhibited a single transport component for arginine consistent with the transport properties of system y ϩ /hCAT-1 (data not shown). In addition, we found predominant expression of hCAT-1 mRNA and only a very low expression of hCAT-2B mRNA in these cells (data not shown). Therefore, hCAT-1 seems to be the prominent transport entity for arginine expressed in DLD-1 cells. PMA does not seem to enhance the degradation of hCAT-1 because inhibition of protein synthesis prior and during PMA treatment did not augment the PMA effect. An unchanged protein turnover is also supported by Western blot analysis showing no change in hCAT-1 protein during the combined PMA and cyclohexamide treatment. In washout experiments arginine transport recovered quickly, again without changing the expression of hCAT-1 protein. This strongly suggests that the internalized transporter remains functional and can recycle back to the plasma membrane. The PMA effect on hCAT-1 is thus clearly different from its effect on other membrane proteins such as the dopamine transporter that is rapidly degraded after PKC activation and where blockage of protein synthesis increases transport inhibition by PMA (18) . Internalization and subsequent degradation of dopamine transporter are dependent on the functional GTPase dynamin, which plays an essential role in the formation of endocytotic vesicles from clathrin coated pits (19) . Interestingly, internalization of the murine CAT-1 (which serves also as virus recep- FIG. 5 . Quantification of the PMA-induced internalization of hCAT-1 expressed endogenously in human DLD-1 colon carcinoma cells. Confluent DLD-1 colon carcinoma cells were grown in 10-cm dishes. Cell treatment and separation of cell surface proteins was performed as specified in the legend to Fig. 3 . A, Western blots were performed with total cell lysates (two upper panels) (80 g/lane) and cell surface proteins (two lower panels) separated by 10% SDS-PAGE. Lysates in the last lane (dimethyl sulfoxide (DMSO) ϩ N-glycosidase F) were treated with N-glycosidase F prior to SDS-PAGE. The blots were probed with an anti-hCAT-1 antibody (upper panel of each group). Black and white arrows indicate the glycosylated and deglycosylated hCAT-1 protein, respectively. The blots were subsequently stripped and probed with an anti-tubulin antibody as control (lower panel of each group). B, quantification of the protein expression was performed as specified in the legend to Fig. 3 (means Ϯ S.E., n ϭ 6 -8). White bars, Me 2 SO control; black bars, PMA; gray bars, PMA plus BIM I. Statistical analysis was performed using analysis of variance with the Bonferroni post hoc test. **, p value Ͻ 0.01 between samples treated with PMA only and with PMA plus BIM I; † †, p value Ͻ 0.01 between PMA-treated total cell lysates and cell surface proteins. tor) (15) in response to binding of viral envelope protein does not involve dynamin and clathrin coated pits (20) . This suggests that also PKC-mediated internalization of CAT-1 might involve a dynamin-independent pathway and hence explain the differential effect of PMA on the two transporters.
Third, the inhibitory effect of PKC activation does not seem to be the result of a direct phosphorylation of hCAT-1. The PKC-induced internalization and reduction in transport was also observed in the mutant hCAT-1 lacking all three potential intracellular PKC-binding sites. When searching the primary sequence of hCAT-1, a total of five consensus sequences for PKC phosphorylation are found. However, the first two sequences are in the third extracellular loop that contains confirmed glycosylation sites and also serves as a virus-binding site in the murine orthologues that function also as receptors for ecotropic murine leukemia viruses (21) . This loop is therefore without doubt extracellular, and phosphorylation of the two sites by PKC is very unlikely. Incubating cells with radiolabeled orthophosphate resulted in labeling of hCAT-1⅐EGFP, but the extend of the phosphorylation was unchanged upon PMA treatment. This supports the notion that PKC phosphorylates hCAT-1 neither directly nor indirectly. In Western blots with immunoprecipitated hCAT-1⅐EGFP, a signal was only detected with an antibody directed against phosphotyrosine but not phosphorylated serine or threonine (data not shown). As expected, the phosphotyrosine signal did not change upon PMA treatment. PKC may thus act on putative regulatory proteins governing transporter localization. Proteins reported to interact with CAT-1 are caveolin, endothelial NO synthase, and actin (for review see Ref. 22) . However, it is not known whether these interactions are influenced by PKC activation and whether they alter the cell surface expression of CAT-1. It needs also to be elucidated whether CAT-1 interacts with one of the candidate proteins for conveying PKC effects on other transporters, e.g. the synaptic membrane protein syntaxin 1A, other soluble NSF attachment protein receptor proteins, the receptor for activated C kinase, or protein phosphatase 2A (23) (24) (25) (26) (27) (28) .
It is noteworthy that activation of PKC has opposite effects on system y ϩ -mediated arginine transport in different cell types. Our preliminary experiments indicate that PKC activation decreases also the activity of the other y ϩ carriers, CAT-2B and CAT-3 (data not shown). It seems therefore unlikely that a PKC-induced up-regulation of system y ϩ activity would be due to expression of different carrier proteins. The PMA-induced up-regulation of system y ϩ -mediated transport in human umbilical vein endothelial cells (29) and human Caco intestinal epithelial cells (30, 31) occurs only after several hours and requires protein synthesis. It might thus be due to increased CAT-1 protein expression. A massive induction of CAT-1 mRNA upon PMA treatment has been observed in B-lymphocytes (32) and EA.hy926 endothelial cells (13) . Although the increased CAT-1 mRNA in EA.hy926 cells is not translated into protein, this might be different in other cell types or under different experimental conditions, particularly because translation of the CAT-1 mRNA is extensively controlled by nutrient supply (12) . However in rat, rabbit, and mouse peritoneal macrophages, a fast up-regulation of system y ϩ activity independent of protein synthesis has been observed, suggesting activation or cell surface recruitment of pre-existing transporter protein (33) . The abundance of hCAT-1 in intracellular membranes observed in the present study makes the latter mechanism very likely. Together with our finding of an indirect PKC action on hCAT-1 activity, the opposite effects of PKC on system y ϩ activity in different cell types might be explained by differences in the complement of intermediate proteins conveying the respective PKC effect.
To our knowledge, this is the first report demonstrating a regulation of the subcellular localization of CAT-1. Recycling of pre-existing transporter protein from intracellular membranes to the cell surface might underlie the protein synthesis-independent up-regulation of arginine transport discussed in the previous paragraph. It will be interesting to see whether other physiological stimuli such as growth factors lead to changes in the subcellular localization of the transporter. At this point, it is difficult to predict whether the magnitude of the PKC-in- duced hCAT-1 inhibition is large enough to have an impact on metabolic pathways dependent on cationic amino acids, such as protein, NO, urea, and polyamine synthesis. Most changes of cationic amino acid transport activity reported in response to various external stimuli are in the same order of magnitude. At least for arginine, accumulating evidence points to the existence of distinct compartments within cells (8, 9, 34, 35) . It is therefore tempting to speculate that PKC activation might only affect a subset of hCAT-1 coupled to specific downstream metabolic pathways.
In conclusion, our results demonstrate that PKC activation leads to an internalization of hCAT-1, independent of PKC consensus sequences in hCAT-1 and concomitant with a decrease in the transport rate for cationic amino acids. PKC seems to have an indirect effect on hCAT-1 because phosphorylation of the transporter was not increased upon PKC activation. Finally, PMA-treated cells recovered arginine transport activity after removal of PMA. The hCAT-1 expression was unchanged during the washout, indicating that the PKC effect is reversible. Internalization of hCAT-1 in response to external stimuli represents a new regulatory mechanism for this tightly controlled transporter.
